Fig 2. Incidence of necroinflammation ≥ 2, or fibrosis ≥ 2 or a combination of both ≥ G2 and S2.

Significant levels of necroinflammation (≥ G2), fibrosis (≥ S2), and necroinflammation (≥ G2) and fibrosis (≥ S2) occurred in 24.9%, 41.2%, and 23.2%, respectively, in HBeAg-positive patients. Significant levels of necroinflammation (≥ G2), fibrosis (≥ S2), and necroinflammation (≥ G2) and fibrosis (≥ S2) were seen in 17.9%, 52.9%, and 17.9%, respectively, of the HBeAg-negative patients.